HDAC9 and breast carcinoma: The most significant correlations were found with belinostat, an HDAC inhibitor mainly used for the treatment of peripheral T cell lymphoma51, and with talazoparib, a PARP inhibitor used for the treatment of advanced breast cancer with germline BRCA mutation52.